Humana IncNYSE: HUM
Health Care · Managed Health Care
$377.00
-0.86%
Vol: 189K
Research Digest
Tuesday, June 16, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14Humana agreed to divest its minority interest in hospice provider Gentiva for roughly $900 million, sharpening focus on its core insurance business as shares rally.Positive▶
Humana announced on June 10, 2026 a definitive agreement with a consortium of investors to divest all or substantially all of its minority interest in Gentiva, the leading U.S. provider of end-of-life services, valuing the stake at approximately $900 million. Proceeds will be used for general corporate purposes, signaling a strategic shift back toward Humana's core health insurance and CenterWell operations. The move comes as the stock has climbed roughly 18% over an eight-day winning streak to around $379. Analysts raised price targets, with JPMorgan lifting its target to $316 from $214 and Mizuho to $390 from $335. The company also secured a contract to join Illinois' Medicaid program, supporting growth in government-backed plans. Key risk remains profitability pressure and lowered 2026 EPS guidance amid an uncertain Medicare Advantage margin environment.
May 21Humana stock surges ~48% on month; analysts hike targets after MA tailwindsPositive▶
HUM trades around $310 (May 19 high $313.19) after a roughly 48% one-month surge driven by favorable Medicare Advantage decisions and Q1 results that affirmed FY2026 adjusted guidance. Q1 revenue rose to $39.65B from $32.11B YoY with adjusted EPS of $10.31 (beat). CVRx announced Humana MA coverage for Barostim therapy effective May 1. Humana is positioned to potentially end 2026 as the largest MA insurer, though analysts flag rising medical cost concerns and leverage.
May 20No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 19Humana partners with VFW, CenterWell, and USAA on May 19 to host service projects across three cities supporting homeless veterans.Positive▶
On May 19, 2026, Humana, alongside CenterWell, USAA and the VFW, will host service projects in three cities to aid homeless veterans, leveraging the company's Medicare Advantage veteran-focused product positioning. The announcement follows Piper Sandler's May 13 PT hike to $254 (from $182) after Q1 adjusted EPS of $10.31 (beat consensus of $10.20) on revenue of $39.65B (up 24% YoY). Individual MA membership grew ~1.14M members (~22% YTD). HUM has surged 48% in the past month. Bear case: stock has run hard and rich-valuation risk persists if MA medical-cost trend reaccelerates into 2H.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15Humana issues Medicare Advantage coverage policy for CVRx Barostim therapy effective May 1, extending reach to 5.2M MA members.Mixed▶
Humana on May 14 announced a Medicare Advantage coverage policy for CVRx Barostim therapy effective May 1, expanding coverage to its 5.2 million Medicare Advantage members across 46 states, including patients in the BENEFIT-HF heart failure trial. Q1 2026 revenue jumped to $39.65B (up from $32.11B YoY), with net income of $1.19B; the company affirmed full-year guidance with lowered EPS outlook to at least $8.36. The board declared a $0.885 cash dividend payable July 31. Raymond James raised its price target to $260 from $230, and JPMorgan lifted to $214 from $180 in early May. Risk: Medicare Advantage margin pressure and lowered EPS guidance.
May 14Humana stock surges to $304 on May 13 with Piper Sandler PT hike to $254 and CenterWell pharmacy partnership with Mark Cuban's Cost Plus DrugsPositive▶
Humana stock climbed 3.38% to $304.74 on May 13, 2026 after Piper Sandler raised its price target to $254, citing the strong Q1 earnings beat and positive Medicare Advantage trends. The company announced a notable pharmacy partnership where its CenterWell pharmacy unit will serve as distributor for Mark Cuban's Cost Plus Drugs platform. Q1 2026 results showed revenue rising to $39.65 billion from $32.11 billion prior year, while net income eased to $1.19 billion and diluted EPS slipped to $9.83. Humana completed a $276.13 million buyback of 1,200,726 shares and lowered 2026 GAAP diluted EPS guidance to at least $8.36. Multiple analysts hiked PTs in early May: TD Cowen to $211 (from $173), JPMorgan to $214 (from $180), Raymond James to $260 (from $230). Progress continues toward 3%+ margin target by 2028. 52-week range is $163.11-$315.35.
May 13Humana stock holds near $277 as analysts raise targets following Q1 beat and reaffirmed 2026 guidancePositive▶
As of May 11, 2026, Humana traded around $276.93 after multiple analyst upgrades in early May, with Raymond James raising its target to $260 from $230, JPMorgan to $214 from $180, and TD Cowen to $211 from $173. The Q1 2026 print delivered $39.65 billion in revenue (up from $32.11 billion a year earlier), $1.186 billion in net income, and adjusted EPS of $10.31 versus the $10.20 consensus. Management reaffirmed full-year 2026 adjusted guidance while lowering GAAP diluted EPS guidance to at least $8.36 on cost pressures. Humana completed a $276 million buyback of about 1.2 million shares during the quarter. The company remains focused on Medicare Advantage growth with about 17 million members and is expected to potentially close 2026 as the largest MA insurer.
May 12Humana lowers 2026 EPS guidance to at least $8.36 as analysts raise targets, prices $1B junior subordinated notesMixed▶
Humana lowered its full-year 2026 EPS guidance to at least $8.36 after Q1 2026 revenue of $39.65B and net income of $1.186B. The company completed a $276.13M share repurchase and priced a $1.0B junior subordinated notes offering due 2056. Despite reduced guidance, multiple analysts raised price targets in early May: TD Cowen to $211 from $173, JPMorgan to $214 from $180, and Raymond James to $260 from $230. Stock trading around $277, hitting $284 intraday on May 12. Board declared $0.885/share dividend payable July 31. JPMorgan rates Hold while Mizuho maintains Buy.
May 11Humana stock rises 6.56% after multiple analyst PT hikes and Q1 with 22% MA membership growth, but FY EPS guidance cutPositive▶
Humana reported Q1 2026 revenue of $39.65B and net income of $1.186B with adjusted EPS of $10.31. Individual Medicare Advantage membership grew 22% and revenue grew 23%, but full-year EPS guidance was lowered to at least $8.36. Stock rose 6.56%. On May 1, multiple analysts raised price targets: TD Cowen to $211 from $173, JPMorgan to $214 from $180, Raymond James to $260 from $230. Mizuho maintains Buy; J.P. Morgan and Wells Fargo at Hold. Board declared $0.885 cash dividend payable July 31. Humana could end 2026 as the largest Medicare Advantage insurer. Stock trading at $249.33 May 6; 52-week range $163.11-$315.35.
May 8Humana reports Q1 2026 EPS of $9.83 (GAAP) and $10.31 adjusted, affirms FY guidance; stock surged 12% on 2.48% Medicare Advantage rate increase for 2027.Positive▶
Humana reported Q1 2026 consolidated pretax results with GAAP EPS of $9.83 and adjusted EPS of $10.31, affirming full-year 2026 adjusted financial guidance. The company benefited significantly from a 2.48% Medicare Advantage payment rate increase for 2027, triggering a 12% stock surge. CenterWell Senior Primary Care experienced sequential patient growth of 110,500 (22% increase) including 59,000 patients from completed MaxHealth acquisition. State-based contracts membership grew by 50,000 driven by Michigan, Illinois, and South Carolina program launches. Company completed $1.0 billion public offering of fixed-to-floating rate subordinated notes at 6.625%. Board declared quarterly dividends of $0.885 per share payable April 24 and July 31, 2026.
May 7Humana reported Q1 2026 EPS of $10.31 beating $10.20 forecast but reduced FY 2026 GAAP EPS guidance to at least $8.36 from at least $8.89.Mixed▶
Humana Q1 2026 results showed revenue of $39.65B vs. $39.37B expected and EPS of $10.31 beating $10.20 forecast. However, the company significantly reduced full-year 2026 GAAP EPS guidance from at least $8.89 to at least $8.36, pressuring the stock which fell 2.58% in pre-market despite the earnings beat. Medicare Advantage membership projected to grow 25% compared to 2025. The company announced a partnership with Mark Cuban Cost Plus Drugs and plans to return to sustainable 3% Medicare Advantage margins by 2028.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| UNHUNITEDHEALTH | $408.67 | -0.58% | +5.1% | 19.7x | 0.65 | $373.3B |
| ELVELEVANCE | $397.94 | -0.98% | +2.0% | 13.7x | 0.68 | $87.3B |
| HUMHUMANA | $377.00 | -0.86% | +24.3% | 24.2x | 0.77 | $45.7B |
| CNCCENTENE | $61.22 | -3.44% | +8.9% | 14.2x | 1.09 | $31.3B |
| MOHMOLINA | $202.82 | +0.47% | +9.2% | 21.8x | 0.80 | $10.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.